Pulmonary fibrosis in the aftermath of the COVID-19 era (Review)

Link to article at PubMed

Exp Ther Med. 2020 Sep;20(3):2557-2560. doi: 10.3892/etm.2020.8980. Epub 2020 Jul 9.

ABSTRACT

The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical observations need to be carried out in order to evaluate the long-term effects of the COVID-19 acute respiratory distress syndrome (ARDS). Potent clinical and laboratory biomarkers should be studied to be able to predict the subgroup of patients that are going to deteriorate or develop lung fibrosis. The opportunity of personalized medicine is a good way to consider for these patients.

PMID:32765748 | PMC:PMC7401793 | DOI:10.3892/etm.2020.8980

Leave a Reply

Your email address will not be published.